ReviewInternational journal of molecular medicine2022
Overview of the immunological mechanism underlying severe fever with thrombocytopenia syndrome (Review).
Review in International journal of molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- A meta-analysis-informed diagnostic stratification tool for invasive pulmonary aspergillosis in severe fever with thrombocytopenia syndrome: systematic review, meta-analysis, and single-center cohort-based assessment.Frontiers in cellular and infection microbiology · 2026Pooled it
- A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV.Emerging microbes & infections · 2026Article
- Integrative analysis of mortality risk in SFTS using machine learning and genetic approaches.mSphere · 2026Article
- Association between serum calcium and in-hospital mortality in patients with severe fever with thrombocytopenia syndrome: a retrospective cohort study.Virology journal · 2026Article
- Construction of a novel prognostic model for severe fever with thrombocytopenia syndrome patients based on inflammatory indicators.BMC infectious diseases · 2026Article
- Unraveling the complexities: A comprehensive review of severe fever with thrombocytopenia syndrome and its associated complications.iScience · 2026Review
- Heterogeneity of lymphoid cells in PBMCs in the acute phase of SFTS: Single-cell transcriptome profiling.Journal of biomedical research · 2026Article
- Procalcitonin/albumin to urea nitrogen ratio: a novel prognostic indicator for severe fever with thrombocytopenia syndrome.BMC infectious diseases · 2026Observational
- Multi-Epitope mRNA Vaccine TargetingBioinformatics and biology insights · 2026Article
- A Novel Machine Learning Approach for Predicting Prognosis of SFTS Patients in the Early Stages of Disease.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- NLPR as a predictor of poor prognosis in patients with severe fever with thrombocytopenia syndrome: a prospective longitudinal study.Frontiers in cellular and infection microbiology · 2026Article
- Development and Validation of a Novel Predictive Model and Simplified Clinical Indicator for Mortality in Severe Fever with Thrombocytopenia Syndrome Patients.Infection and drug resistance · 2026Article
- Early mortality risk prediction in severe fever with thrombocytopenia syndrome using an interpretable machine learning model based on routine clinical parameters.Frontiers in public health · 2026Article
- Epidemiological analysis and risk factors of recurrent pulmonary tuberculosis in Western Zhejiang Province, China (2007-2024).Frontiers in public health · 2026Article
- Integration of SFTSV Viral Load, Age, and Double-Negative B-Cells as Prognostic Biomarkers for Severe Fever With Thrombocytopenia Syndrome Outcomes.Journal of immunology research · 2026Article
- Neurological Manifestations and High Viral Load as Independent Predictors of Mortality in Severe Fever With Thrombocytopenia Syndrome.Open forum infectious diseases · 2026Article
- A single-chain mRNA vaccine co-expressing GPC and NP provides complete protection against lethal Dabie bandavirus challenge in mice.Molecular therapy. Nucleic acids · 2025Article
- Neurological manifestations and MMP8 as a prognostic biomarker in severe fever with thrombocytopenia syndrome.PLoS neglected tropical diseases · 2025Article
- Blood transcriptomic profiling reveals gene expression alterations in patients with SFTS-associated encephalitis.Microbiology spectrum · 2025Article
- Current status of severe fever with thrombocytopenia syndrome in China (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) has been acknowledged as an emerging infectious disease that is caused by the SFTS virus (SFTSV). The main clinical features of SFTS on presentation include fever, thrombocytopenia, leukocytopenia and gastrointestinal symptoms. The mortality rate is estimated to range between 5‑30% in East Asia. However, SFTSV infection is increasing on an annual basis globally and is becoming a public health problem. The transmission cycle of SFTSV remains poorly understood, which is compounded by the pathogenesis of SFTS not being fully elucidated. Since the mechanism underlying the host immune response towards SFTSV is also unclear, there are no effective vaccines or specific therapeutic agents against SFTS, with supportive care being the only realistic option. Therefore, it is now crucial to understand all aspects of the host‑virus interaction following SFTSV infection, including the antiviral states and viral evasion mechanisms. In the present review, recent research progress into the possible host immune responses against SFTSV was summarized, which may be useful in designing novel therapeutics against SFTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.